vxrt stock price forecast narratives in financial media point to macro headwinds such as interest rate policy, which can compress valuations for growth-oriented biotech firms. Using the 2 Stage Free Cash Flow to Equity, Vaxart fair value estimate is US$0.90 Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Chartists observe vxrt stock price forecast levels aligning with a potential double bottom pattern, a technical setup often preceding upward price momentum.
